BioPharma, Pharma Gearing Up to Challenge Pfizer in a Rare Disease, BridgeBio Secures Up to $1.25B By Frank Vinluan
BioPharma, Pharma BMS builds on BridgeBio alliance, inking deal for rights to KRAS cancer drug By Frank Vinluan
BioPharma, Pharma Heart drug’s trial failure busts bid to best Pfizer, but BridgeBio still bets on coming data By Frank Vinluan
BioPharma, Pharma, Daily Anji Pharma adds $70M for clinical trials, expansion of ‘hub and spoke’ biz model By Frank Vinluan
BioPharma, Pharma Centessa Pharma’s IPO brings in $330M for its new model of drug R&D By Frank Vinluan
BioPharma BridgeBio turns Alexion asset into first approved drug for rare metabolic disease By Frank Vinluan
BioPharma, Pharma Lycia Therapeutics Lands $106M for Protein Degraders That Treat Autoimmune & Inflammatory Diseases By Frank Vinluan
BioPharma, Pharma FDA Rejection Is a Delay, Not a Detour for Alnylam’s Aim to Treat Heart Disorder By Frank Vinluan
BioPharma, Pharma Star Therapeutics Lands $90M to Expand Its Drug Discovery Universe By Frank Vinluan
BioPharma, Pharma Immunology & Inflammation Biotech Apogee Plans IPO to Demo Dosing Edge in Eczema By Frank Vinluan
BioPharma, Pharma FDA approves Taiho drug for rare bile duct cancer with certain genetic signature By Frank Vinluan
BioPharma, Pharma Alnylam drug succeeds in heart study, setting stage for FDA filing and showdown with Pfizer By Frank Vinluan
